Last reviewed · How we verify
Escitalopram, venlafaxine
This combination of escitalopram (an SSRI) and venlafaxine (an SNRI) increases serotonin and norepinephrine levels in the brain to treat depression and anxiety disorders.
This combination of escitalopram (an SSRI) and venlafaxine (an SNRI) increases serotonin and norepinephrine levels in the brain to treat depression and anxiety disorders. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Escitalopram, venlafaxine |
|---|---|
| Sponsor | K. Lieb |
| Drug class | SSRI/SNRI combination |
| Target | Serotonin transporter (SERT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Escitalopram selectively inhibits serotonin reuptake at the presynaptic membrane, while venlafaxine inhibits reuptake of both serotonin and norepinephrine. Together, they increase synaptic concentrations of these monoamine neurotransmitters, which are thought to underlie their antidepressant and anxiolytic effects. This combination approach may provide broader neurochemical coverage than either agent alone.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Social anxiety disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Sexual dysfunction
- Dizziness
- Sweating
- Tremor
- Hypertension (venlafaxine component)
Key clinical trials
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escitalopram, venlafaxine CI brief — competitive landscape report
- Escitalopram, venlafaxine updates RSS · CI watch RSS
- K. Lieb portfolio CI